Platinum

EC 231-116-1

projects tracked
2
active
2
producing plant
1

Also known as Pt.

Platinum projects

chemXplore tracks 2 projects producing platinum, of which 2 are active.

  1. none Announced / Concept
  2. none FEED / Pre-FID
  3. 1 project FID / Sanctioned
  4. none Under Construction
  5. 1 project Commissioning & Start-up

Of the active ones, 1 new construction and 1 expansion.

What moved recently

  • 12 November 2026 Umicore Hoboken Precious Metals Refining flowsheet expansion · FID / Sanctioned · Belgium
  • March 2026 Johnson Matthey Royston Third Century Refinery (3CR) new PGM refinery · Commissioning & Start-up · United Kingdom

Latest news on platinum

19 November 2026
Johnson Matthey lifts full-year profit outlook after first-half growth

Operating profit rose 45% to £170 million, while Clean Air margins improved and the group advanced its portfolio reshaping.

17 November 2026
GSK wins US approval for Nelkarmi in previously treated ALK-positive lung cancer

The accelerated approval covers adults with advanced disease after alectinib alone, or after at least two ALK inhibitors and platinum chemotherapy.

12 November 2026
Umicore plans €450m Hoboken expansion and operating-model changes

The project adds cobalt recycling and targets €60m in annual savings by Q4 2028; FY 2026 adjusted EBITDA guidance remains slightly above €1bn.

12 November 2026
Asahi Kasei, Circularise and Furuya Metal test precious-metal traceability

The project will track iridium and ruthenium from spent electrodes through refining and reuse in new electrodes.

26 October 2026
Merck’s sacituzumab tirumotecan improves survival vs chemotherapy in advanced/recurrent endometrial cancer

Phase 3 TroFuse‑005 showed a 32% lower risk of death and 41% lower risk of progression or death, with a PDUFA target date of June 15, 2027.

25 October 2026
Lilly's olomorasib shows durable first-line activity in KRAS G12C NSCLC

Durable PFS and DOR not reached with immunotherapy combo; chemoimmunotherapy combo showed 62% ORR and 14.5‑month median DOR in first-line KRAS G12C NSCLC.

24 October 2026
Lilly's Sofetabart Mipitecan shows 79% cORR in platinum‑sensitive ovarian cancer

Sofe‑M plus bevacizumab produced a 79% confirmed objective response rate and 100% disease control in platinum‑sensitive ovarian cancer, with activity across FRα levels and prior PARPi exposure.

24 October 2026
Amgen: IMDELLTRA plus IMFINZI cuts death risk 58% in first‑line maintenance ES‑SCLC

Phase 3 DeLLphi‑305: IMDELLTRA with durvalumab raised median OS to 21.1 vs 12.7 months, tripled PFS, and produced ~80% one‑year survival versus 53%.

23 October 2026
GSK Mo‑Rez shows 62% confirmed response and 12.2‑month median DoR in platinum‑resistant ovarian cancer

Phase Ib BEHOLD‑1 reports durable responses and 11.1‑month median PFS at the selected phase III dose; safety predominantly haematologic with most grade ≥3 events.

13 October 2026
Merck unveils first Phase 3 results for intismeran and sac‑TMT at ESMO 2026

Phase 3 intismeran combo improved recurrence‑free and distant metastasis‑free survival in resected stage IIB–IV melanoma; sac‑TMT and KEYNOTE‑C93 report pivotal endometrial cancer findings; >90 additional abstracts.

Platinum plants by country

chemXplore tracks 1 plant producing platinum in 1 country.

plants

A subscription lists every plant we track for platinum, with its owners and capacity. What a subscription does